Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05170334 · ClinicalTrials.gov registry record · Phase 2

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

A Phase 2 study of Metastatic Uveal Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Active
Registry status
Phase 2
Development phase
7
Enrollment target
1
Study location

NCT05170334: Active Phase 2 study of Metastatic Uveal Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

NCT05170334 is a Phase 2 study of Metastatic Uveal Melanoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 7 participants, below the 132-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05170334, a Phase 2 study of Metastatic Uveal Melanoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.

Primary Outcome

Overall Response Rate (ORR) defined as proportion of patients to have achieved a complete or partial response per RECIST v1.1 criteria.

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • DRUG Belinostat
  • DRUG Binimetinib

Study Locations (1)

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2021-12-15
Est. Completion 2028-01
Phase Phase 2
H. Lee Moffitt Cancer Center and Research Institute

502 total trials

What the registry record for NCT05170334 still lists

NCT05170334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 132-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Belinostat is the first listed.

NCT05170334 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05170334 about?

NCT05170334 is a clinical study titled "Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma". This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.

What is the current status of trial NCT05170334?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-12-15. Estimated completion is 2028-01.

What conditions does trial NCT05170334 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT05170334?

The interventions under investigation include: Belinostat (DRUG), Binimetinib (DRUG).

Who is sponsoring clinical trial NCT05170334?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05170334 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05170334's enrollment target sits among peer trials

7 15th of 14 the lowest of 14 other Metastatic Uveal Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05170334, the US trial registry maintained by the National Library of Medicine. NCT05170334 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.